JP2012506051A5 - - Google Patents

Download PDF

Info

Publication number
JP2012506051A5
JP2012506051A5 JP2011532094A JP2011532094A JP2012506051A5 JP 2012506051 A5 JP2012506051 A5 JP 2012506051A5 JP 2011532094 A JP2011532094 A JP 2011532094A JP 2011532094 A JP2011532094 A JP 2011532094A JP 2012506051 A5 JP2012506051 A5 JP 2012506051A5
Authority
JP
Japan
Prior art keywords
lipoprotein
insulin resistance
parameters
risk
score
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011532094A
Other languages
English (en)
Japanese (ja)
Other versions
JP5393798B2 (ja
JP2012506051A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/005689 external-priority patent/WO2010047767A2/en
Publication of JP2012506051A publication Critical patent/JP2012506051A/ja
Publication of JP2012506051A5 publication Critical patent/JP2012506051A5/ja
Application granted granted Critical
Publication of JP5393798B2 publication Critical patent/JP5393798B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011532094A 2008-10-20 2009-10-20 リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム Active JP5393798B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10683308P 2008-10-20 2008-10-20
US61/106,833 2008-10-20
PCT/US2009/005689 WO2010047767A2 (en) 2008-10-20 2009-10-20 Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same

Publications (3)

Publication Number Publication Date
JP2012506051A JP2012506051A (ja) 2012-03-08
JP2012506051A5 true JP2012506051A5 (enExample) 2012-12-06
JP5393798B2 JP5393798B2 (ja) 2014-01-22

Family

ID=42109358

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011532094A Active JP5393798B2 (ja) 2008-10-20 2009-10-20 リポタンパク質インスリン抵抗性指数、ならびに同一物を生成するための関連する方法、システムおよびコンピュータプログラム

Country Status (7)

Country Link
US (1) US8386187B2 (enExample)
EP (2) EP4016105A1 (enExample)
JP (1) JP5393798B2 (enExample)
KR (1) KR20110086074A (enExample)
AU (1) AU2009308124B2 (enExample)
CA (1) CA2741034C (enExample)
WO (1) WO2010047767A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same
SG10201608139VA (en) 2011-06-30 2016-11-29 Liposcience Inc Quantitative nmr clinical analyzers with automatic nmr temperature sensitivity compensation that accommodate large ambient operational temperature ranges
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
US9483611B2 (en) 2012-04-27 2016-11-01 Liposcience, Inc. Protective HDL particle number evaluations
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9551768B2 (en) 2013-03-15 2017-01-24 East Carolina University NMR method for monitoring changes in the core of lipoprotein particles in metabolism and disease
JP6696907B2 (ja) * 2014-01-06 2020-05-20 リポサイエンス,インコーポレイテッド 糖尿病への転化を予測する多重マーカリスクパラメータ
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
MX392384B (es) 2014-03-28 2025-03-24 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
CN107110939B (zh) 2014-09-11 2021-05-14 力保科学公司 用于测定心血管疾病或事件的风险参数的系统
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
KR102539142B1 (ko) 2016-09-05 2023-06-01 삼성전자주식회사 스펙트럼 분석 장치와 방법, 및 혈당 측정 장치
US10775458B2 (en) 2018-03-05 2020-09-15 Texas Tech University System Method and system for non-invasive measurement of metabolic health
WO2022089749A1 (en) * 2020-10-29 2022-05-05 Telefonaktiebolaget Lm Ericsson (Publ) Checking state consistency in a log replication configuration
CN113117241B (zh) * 2021-04-15 2022-01-28 中国科学院合肥物质科学研究院 一种提高胰岛素水平和敏感性的磁场发生装置及其应用
CN115188493A (zh) * 2022-07-13 2022-10-14 天津市人民医院 一种胰岛素抵抗预测模型的构建系统、方法及应用
WO2024097429A1 (en) * 2022-11-05 2024-05-10 Texas Tech University System Methods and tools for assessing cardiometabolic health and hidden disease risk among apparently healthy individuals
CN120613144B (zh) * 2025-05-27 2026-02-03 中国科学院精密测量科学与技术创新研究院 一种基于血液nmr编辑谱的药物敏感度预测方法
CN120280166A (zh) * 2025-06-10 2025-07-08 南昌大学第二附属医院 术后胰岛素抵抗风险预测模型的构建方法及系统

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4933844A (en) 1988-09-26 1990-06-12 Otvos James D Measurement of blood lipoprotein constituents by analysis of data acquired from an NMR spectrometer
WO1993003450A1 (en) * 1991-07-30 1993-02-18 North Carolina State University Method and apparatus for measuring blood lipoprotein levels by nmr spectroscopy
US6653140B2 (en) * 1999-02-26 2003-11-25 Liposcience, Inc. Methods for providing personalized lipoprotein-based risk assessments
ES2256000T3 (es) 1999-04-22 2006-07-16 Liposcience, Inc. Procedimiento de rmn para determinar el riesgo de desarrollar diabetes tipo 2.
US7395158B2 (en) * 2000-05-30 2008-07-01 Sensys Medical, Inc. Method of screening for disorders of glucose metabolism
US6890905B2 (en) * 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
WO2003012416A1 (en) * 2001-08-01 2003-02-13 Liposcience, Inc. Method of determining presence and concentration of lipoprotein x in blood plasma and serum
ATE525635T1 (de) * 2001-11-13 2011-10-15 Univ California Ionenmobilitätsanalyse biologischer partikel
US7243030B2 (en) 2002-10-25 2007-07-10 Liposcience, Inc. Methods, systems and computer programs for deconvolving the spectral contribution of chemical constituents with overlapping signals
DE10315877B4 (de) * 2003-04-08 2005-11-17 Roche Diagnostics Gmbh Krankheitsverlaufkontrolle
FR2853911B1 (fr) * 2003-04-17 2005-07-08 Merck Sante Sas Gene induit par l'insuline, comme cible therapeutique dans le diabete
AU2004276791B2 (en) * 2003-09-23 2010-07-01 Beth Israel Deaconess Medical Center Screening for gestational disorders
EP1735631A2 (en) * 2004-04-01 2006-12-27 Liposcience, Inc. Nmr clinical analyzers and related methods, systems, modules and computer program products for clinical evaluation of biosamples
US9372190B2 (en) * 2004-05-26 2016-06-21 Region Nordjylland Method of evaluation of the relative risk of developing atherosclerosis in patients
DE102004026903B4 (de) * 2004-06-01 2006-05-18 Universität Regensburg Verfahren zur Bestimmung von Lipoproteinen in Körperflüssigkeiten und Messanordnung dafür
CA2574791A1 (en) * 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
JP4210855B2 (ja) * 2004-09-28 2009-01-21 大塚製薬株式会社 インスリン抵抗性の評価方法
US7323296B2 (en) * 2004-10-01 2008-01-29 Yuanhong Ma Method and index for diagnosing insulin resistance
EP1645877A1 (en) * 2004-10-08 2006-04-12 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for providing a insulin resistance biomarker profile of one or more lipids
EP1872138A1 (en) 2005-04-11 2008-01-02 AstraZeneca AB A method and a kit for diagnosing type 2 diabetes, metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes.
WO2007133593A2 (en) * 2006-05-10 2007-11-22 Liposcience, Inc. Methods, systems and computer programs for assessing chd risk using weighted hdl particle number measurements
MX2010000414A (es) * 2007-07-17 2010-04-01 Metabolon Inc Biomarcadores para prediabetes, enfermedades cardiovasculares y otros trastornos relacionados con sindrome metabolico, y metodos de uso de los mismos.
US20090191576A1 (en) * 2008-01-28 2009-07-30 Yuanhong Ma Method and index for diagnosing insulin resistance
WO2010047767A2 (en) 2008-10-20 2010-04-29 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods, systems and computer programs for generating same

Similar Documents

Publication Publication Date Title
Cerezuela-Espejo et al. Are we ready to measure running power? Repeatability and concurrent validity of five commercial technologies
Crotty et al. Reliability and validity of the lactate pro 2 analyzer
Merry et al. The validity and reliability of two commercially available load sensors for clinical strength assessment
JP2015522806A5 (enExample)
JP2015524917A5 (enExample)
Wang et al. Characterization of human plasma proteome dynamics using deuterium oxide
De Simone et al. Allometric normalization of cardiac measures: producing better, but imperfect, accuracy
Watkins et al. Concurrent validity and reliability of three ultra-portable vertical jump assessment technologies
JP2012515898A5 (enExample)
Araujo-Moura et al. Blood pressure measurement in pediatric population: comparison between automated oscillometric devices and mercury sphygmomanometers—a systematic review and meta-analysis
CN107945878A (zh) 一种基于放射组学的肝静脉压力梯度计算模型的构建方法
JP5199685B2 (ja) 健康診断の検査値換算プログラム
Held et al. Reliability of the maximal lactate accumulation rate in rowers
JP2021508048A5 (enExample)
Rodrigues Filho et al. Evaluating the impact of measurement uncertainty in blood pressure measurement on hypertension diagnosis
JP2025066131A (ja) マルチパラメータ代謝脆弱性指数評価
Cai et al. Association Between Cardiovascular Biological Age and Cardiovascular Disease―A Prospective Cohort Study―
Knight et al. Epidemiologic monitoring of prenatal screening for neural tube defects and Down syndrome
Drobnič et al. The validity of a three-dimensional motion capture system and the garmin running dynamics pod in connection with an assessment of ground contact time while running in place
Tang et al. Metabolite Fusion between Breath and Blood Enables More In-Depth Understanding of the Endogenous Metabolome
TW201516725A (zh) 單一核苷酸多型性疾病發生率預測系統
Eriksen et al. A maximal cycle test with good validity and high repeatability in adults of all ages
US20170316176A1 (en) Device for analyzing insulin secretion ability, system for analyzing insulin secretion ability provided with same, and method for analyzing insulin secretion ability
JP2009050596A (ja) 腹囲推定装置
US8380297B2 (en) System for measuring a user's percentage of body fat